Zevra Therapeutics, Inc.
ZVRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.94 | -0.00 | 0.36 | 1.08 |
| FCF Yield | 0.78% | -0.79% | -2.05% | -3.63% |
| EV / EBITDA | 368.61 | 6.17 | 252.60 | -28.69 |
| Quality | ||||
| ROIC | 1.69% | -30.27% | -3.66% | -10.67% |
| Gross Margin | 94.04% | 52.17% | 93.41% | 88.66% |
| Cash Conversion Ratio | -8.66 | -0.05 | 2.65 | 0.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 71.06% | 54.43% | 61.31% | 31.19% |
| Free Cash Flow Growth | 208.94% | 54.16% | 48.79% | 10.42% |
| Safety | ||||
| Net Debt / EBITDA | 5.65 | 0.18 | 14.40 | -1.60 |
| Interest Coverage | 2.02 | -35.36 | -2.72 | -7.03 |
| Efficiency | ||||
| Inventory Turnover | 1.14 | 11.17 | 0.53 | 0.69 |
| Cash Conversion Cycle | -504.27 | 71.57 | 226.89 | -653.13 |